---
schema_version: "secwatch.filing_event.v1"
accession: "0001711279-22-000007"
form_type: "8-K"
ticker: "KRYS"
cik: "0001711279"
company_name: "Krystal Biotech, Inc."
filed_at: "2022-02-28T23:59:59+00:00"
generated_at: "2026-06-27T03:43:44.084452+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Krystal Biotech reports FY2021 net loss $69.6M, cash $502.5M; on track for Vyjuvek BLA in 1H 2022

## Summary
- Net loss Q4 2021 $21.8M ($0.94/share); full year $69.6M ($3.13/share) vs. $32.2M ($1.71) in 2020.
- Cash & equivalents $502.5M at Dec 31, 2021, up from $271.3M; net proceeds from public offerings.
- Positive Phase 3 GEM-3 data for Vyjuvek (DEB); BLA filing expected 1H 2022, MAA in 2H 2022.
- Phase 1 trial of KB407 for cystic fibrosis expected to start in Australia 1H 2022; US trial in 2H 2022.
- Suma Krishnan promoted to President R&D effective Feb 25, 2022; she was COO and founder.

## SEC filing metadata
- accession: 0001711279-22-000007
- form_type: 8-K
- ticker: KRYS
- cik: 0001711279
- company_name: Krystal Biotech, Inc.
- filed_at: 2022-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711279/000171127922000007/0001711279-22-000007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711279/000171127922000007/krys-20220225.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001711279-22-000007
- JSON: https://secwatch.observer/filing/0001711279-22-000007.json
- Plain text: https://secwatch.observer/filing/0001711279-22-000007.txt

## Key facts
- Executive change
  Suma M. Krishnan was appointed as President, R&D at Krystal Biotech, Inc..
  - Action: appointed
  - Role: President, R&D
  source text: Effective February 25, 2022, the board of directors of the Company appointed Ms. Suma M. Krishnan, the Company's current Chief Operating Officer, as the Company's President, R&D.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1711279/000171127922000007/0001711279-22-000007-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.